Science & academia milestones | Good News for Humankind

Mycobacterium tuberculosis drug susceptibility test., for article on antibiotic resistance

U.S. scientists restore a last-resort antibiotic’s power over superbugs

By Peter Schulte / July 23, 2026 / Good News For Humankind

Drug-resistant infections already kill more than a million people a year worldwide and contribute to nearly 5 million deaths — a toll projected to climb toward 10 million annually by 2050 if nothing changes. Now researchers at Cold Spring Harbor Laboratory in New York and Scripps Research and in California have found a way to fight back without inventing new drugs: a small companion molecule, pghi-4, that disables a key bacterial defense and lets vancomycin kill resistant bacteria again in lab tests. The approach is years from clinical use, but restoring the antibiotics medicine already has could eventually save millions of lives.

Abstract visual, for article on LSD-based drug

Single dose of LSD-based drug shows significant depression relief in key Phase 3 trial

By Peter Schulte / June 23, 2026 / Good News For Humankind

A single-dose LSD-based drug has just cleared one of medicine’s highest evidentiary bars — offering meaningful, durable relief from major depressive disorder in a rigorous Phase 3 trial. DT120 ODT, a pharmaceutically refined lysergide compound, produced an 8.1-point improvement on the standard depression scale compared to placebo, with nearly all side effects mild and resolving the same day. For the millions who cycle through daily antidepressants without real relief, a single-dose model represents a genuinely different kind of hope — and a signal that psychedelic-assisted medicine is maturing into a serious contender in mainstream psychiatric care.

Filling vaccine syringe, for article on HPV vaccine

England records zero cervical cancer deaths in young women, crediting HPV vaccine

By Peter Schulte / June 18, 2026 / Good News For Humankind

HPV vaccination is proving it can do something remarkable: wipe out a cancer entirely in a generation. England’s school-based program, now nearly two decades old, has driven cervical cancer deaths to zero among women in their early twenties — a cohort where dozens of deaths would otherwise have been expected. Researchers say this is only the beginning, with far greater impact ahead as vaccinated generations age. It’s a powerful reminder that a single vaccine, delivered early enough, can make a whole category of suffering disappear — and that other countries have a clear, proven path to follow.

Mangroves, for article on mangrove recovery

The world’s mangroves have been rebounding since 2010 after decades of decline

By Peter Schulte / June 13, 2026 / Good News For Humankind

Mangrove forests are coming back — and the scale of the recovery is genuinely meaningful. Since 2010, the world has been gaining more mangrove coverage than it loses each year, reversing decades of rapid destruction. These forests do extraordinary work: they absorb carbon at rates that dwarf most land-based forests and shield more than 15 million people annually from storm flooding. Community-led restoration in countries like Senegal and the Philippines has been central to the turnaround. It’s a reminder that ecosystems under pressure can recover quickly when protection, funding, and local knowledge work together.

Depiction of DNA, for article on gene therapy for inherited deafness

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

By Peter Schulte / May 28, 2026 / Good News For Humankind

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families.
In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within six months, and five regained normal hearing, including the ability to hear whispers. Instead of charging the millions per child that’s common for rare-disease therapies, Regeneron chose a different path. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag. Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Professional office, for article on four-day work week

Four-day week cut burnout without cutting output, Australian study finds

By Peter Schulte / May 26, 2026 / Good News For Humankind

Four-day work weeks held up beautifully in a two-year Australian trial just published in a Nature Portfolio journal — 14 of the 15 companies involved decided to keep the shorter week for good. Six actually saw productivity rise, and the rest held steady. The secret wasn’t cramming five days into four, but rethinking the work itself: cutting pointless meetings, automating repetitive tasks, and letting people focus on what mattered. Six of the companies said their main motivation was easing burnout, which a 2025 Beyond Blue survey found affects one in two Australian workers. As AI reshapes what humans actually need to do at work, this quiet experiment suggests a hopeful answer to where those reclaimed hours could go — back to us.

Cancer patient reading a book, for article on pre-surgery immunotherapy

Bowel cancer patients see zero relapses three years after new immunotherapy

By Peter Schulte / May 20, 2026 / Good News For Humankind

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the immune system, sparing them months of post-surgery chemo. One participant described the cancer “melting away” before his operation. If larger trials confirm the approach, it could reshape how a meaningful slice of bowel cancer cases are treated worldwide.

Infant feet, for article on nirsevimab RSV infant hospitalizations

Spanish study links RSV antibody to 86% drop in infant hospitalizations

By Peter Schulte / May 14, 2026 / Good News For Humankind

Nirsevimab, a long-acting antibody given to every infant in one Spanish region, cut RSV hospitalizations by 86% compared to previous seasons, according to a new study out of Valladolid University. Babies under six months — the group hit hardest by RSV every winter — saw the biggest drop, with pediatric intensive care admissions falling sharply too. Unlike a traditional vaccine, the shot delivers ready-made antibodies directly, which matters for newborns whose immune systems are still developing. Several European countries and the U.S. have already added it to routine infant care, and early data abroad echo the Spanish results. The remaining challenge is making sure families in lower-income countries, where RSV hits hardest, aren’t left waiting.

University of Chicago campus, for article on University of Chicago free tuition

University of Chicago expands free tuition to families earning under $250k

By Peter Schulte / May 14, 2026 / Good News For Humankind

Free tuition at the University of Chicago will soon reach families earning up to $250,000 a year — a ceiling roughly two to three times higher than most peer programs. Starting in autumn 2027, qualifying students pay nothing toward tuition, and those from households under $125,000 also get room, board, and fees covered. The move directly addresses the middle-income squeeze, where families often earn too much for traditional aid but too little to absorb a tuition bill north of $65,000 without serious debt. UChicago says it will also simplify the aid process itself, which trips up many families. As elite universities face growing pressure on access, commitments like this one reshape what affordability can look like at the top of American higher education.

Two sets of hand holding newborn baby, for article on Coartem Baby malaria treatment

W.H.O. approves world’s first malaria treatment for newborn babies

By Peter Schulte / May 13, 2026 / Good News For Humankind

Newborn babies with malaria finally have a medicine made just for them. Coartem Baby, a cherry-flavored tablet that dissolves into breast milk or water, just earned World Health Organization prequalification — a green light that opens the door to public health systems across sub-Saharan Africa. For decades, doctors had to guess at doses using drugs built for older children, even as research showed infants were getting infected too. Ghana has already begun rolling it out, and Novartis has committed to what it calls “largely not-for-profit pricing” in malaria-endemic regions. Alongside new vaccines and better bed nets, it’s a quiet but meaningful sign that the fight against malaria — which still kills hundreds of thousands of children a year — is reaching the patients it had long overlooked.